Markets:

Overview

News

Currencies

International

Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

6.310 -0.430 (-6.38%)

Streaming Delayed Price Updated: 9:52 AM EST, Feb 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday ↗

December 31, 2025

One of the company's key drugs won't be challenged by a competing medication anytime soon.

Via The Motley Fool

The market is filled with gapping stocks in Wednesday's session. ↗

December 31, 2025

Via Chartmill

Xeris Biopharma (XERS) Q3 2025 Earnings Transcript ↗

November 06, 2025

Xeris Biopharma (XERS) Q3 2025 Earnings Transcript

Via The Motley Fool

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Posts Record Q3 2025 Revenue but Misses Analyst Estimates ↗

November 06, 2025

Xeris Biopharma posts record Q3 2025 revenue of $74.4M, up 37% YoY, but misses earnings estimates. The company raises full-year guidance.

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Outlook For Xeris Biopharma Holdings ↗

May 07, 2025

Via Benzinga

Earnings Outlook For Xeris Biopharma Holdings ↗

November 07, 2024

Via Benzinga

Earnings Outlook For Xeris Biopharma Holdings ↗

March 05, 2024

Via Benzinga

Xeris (XERS) Q2 Revenue Jumps 49% ↗

August 07, 2025

Via The Motley Fool

Traders are paying attention to the gapping stocks in Thursday's session. ↗

August 07, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance ↗

August 07, 2025

Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to...

Via Chartmill

Topics Earnings

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗

July 07, 2025

XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score.

Via Chartmill

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A High-Growth Stock Meeting Minervini’s Trend Template ↗

May 13, 2025

XERIS BIOPHARMA (XERS) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors.

Via Chartmill

Would Mark Minervini consider XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) a top stock pick? ↗

April 07, 2025

Why the high growth investor may take a look at XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS). A fundamental and technical analysis of (NASDAQ:XERS).

Via Chartmill

Xeris Biopharma - Possibly The Best Pharma Stock ↗

March 11, 2025

The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies.

Via Talk Markets

Topics Stocks / Equities

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In ↗

March 06, 2025

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.

Via Stocktwits

These stocks are gapping in today's session ↗

March 06, 2025

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

Earnings Scheduled For March 6, 2025 ↗

March 06, 2025

Via Benzinga

Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 11, 2024

Via Benzinga

More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying ↗

August 14, 2024

Via Benzinga

Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying ↗

August 13, 2024

Via Benzinga

XERS Stock Earnings: Xeris Biopharma Holdings Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

XERS stock results show that Xeris Biopharma Holdings beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 30, 2024

Via Benzinga

Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying ↗

May 13, 2024

Via Benzinga

XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

XERS stock results show that Xeris Biopharma Holdings missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Why Are Xeris Biopharma Shares Moving Monday? ↗

May 06, 2024

Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics. Xeris said it will work with Beta Bionics to develop and...

Via Benzinga

XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023 ↗

March 06, 2024

XERS stock results show that Xeris Biopharma Holdings met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Earnings Scheduled For March 6, 2024 ↗

March 06, 2024

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.